1. Home
  2. List
Reference Patent

Reference - List

  • 12 Hits
  • Search Condition : Filter (MeSH = Molecular Targeted Therapy / methods)
Species Resource Title
Human and Animal Cells 293T(RCB2202) , SKW-3(RCB1168) ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.
Human and Animal Cells HuCCT1(RCB1960) , TFK-1(RCB2537) Therapeutic implication of HER2 in advanced biliary tract cancer.
Human and Animal Cells PK-8(RCB2700) , KLM-1(RCB2138) Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
Human and Animal Cells ATN-1(RCB1440) , ILT-Mat(RCB0475) , TL-Mor(RCB1881) Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
Human and Animal Cells LMSU(RCB1062) HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer.
Human and Animal Cells HT1080(RCB1956) Development of Organelle Replacement Therapy Using a Stearyl-Polyhistidine Peptide against Lysosomal Storage Disease Cells.
Human and Animal Cells ECC10(RCB0983) , GCIY(RCB0555) , MKN7(RCB0999) Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
Human and Animal Cells C2C12(RCB0987) Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy.
Human and Animal Cells II-18(RCB2093) Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Human and Animal Cells HS-SY-II(RCB2231) Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
Human and Animal Cells TE-8(RCB2098) Esophageal cancer stem cells are suppressed by tranilast, a TRPV2 channel inhibitor.
Human and Animal Cells YSCCC(RCB1549) , TGBC1TKB(RCB1129) , TGBC2TKB(RCB1130) , TGBC14TKB(RCB1186) Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.